Document Classification

Section Type: RESULTS

Text: Fondaparinux compared with enoxaparin reduced fatal bleeding [0. 07 vs. 0. 22 %, relative risk (RR) 0. 30, 95 % CI : 0. 13-0. 71], non-fatal major bleeding (2. 2 vs. 4. 2 %, RR 0. 52, 95 % CI : 0. 44-0. 61), minor bleeding (1. 1 vs. 3. 2 %, RR 0. 34, 95 % CI : 0. 27-0. 42), and need for transfusion (1. 8 vs. 3. 1 %, RR 0. 56, 95 % CI : 0. 47-0. 61) during the first 9 days.